The clinical impact of tumour-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study.
The clinical impact of tumour-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study.
复制标题
DOI：
10.1002/ijc.30869
复制
发表时间：
2017-10-15
影响因子：
6.4
通讯作者：
Jirström K
中科院分区：
文献类型：
--
作者：
Berntsson J;Svensson MC;Leandersson K;Nodin B;Micke P;Larsson AH;Eberhard J;Jirström K
越来越多的证据表明淋巴细胞密集浸润与结直肠癌（CRC）预后之间存在关联，但这种预后影响是否因肿瘤位置而异仍不清楚。本研究调查了细胞毒性和调节性 T 细胞对 CRC 的预后影响，特别是原发肿瘤的解剖亚位点。 CD3+、CD8+ 和 FoxP3+ 肿瘤浸润 T 细胞的密度是在来自前瞻性人群队列的 557 例 CRC 病例的肿瘤组织微阵列中计算的。在右结肠、左结肠和直肠的亚组分析中，应用 Kaplan-Meier 和 Cox 回归分析来确定高和低淋巴细胞密度对 5 年总生存率的影响。高CD8+细胞密度是右侧结肠肿瘤患者的有利预后因素（风险比[HR]=0.53，95%置信区间[CI]0.29-0.95），与年龄、性别、TNM分期、分化等级和血管侵犯无关，CD8+细胞与右侧结肠肿瘤之间存在显着的预后相互作用（p = 0.031）。高FoxP3+细胞密度仅在直肠肿瘤患者中是独立的有利预后因素（HR = 0.54，95% CI 0.30-0.99），CD3+细胞密度是右半结肠和直肠肿瘤的独立有利预后因素，但CD3+或FoxP3+细胞与单侧性之间没有显着的预后相互作用。这些结果表明，结直肠癌中肿瘤浸润淋巴细胞的预后影响因原发肿瘤部位而异，进一步表明肿瘤位置可能是治疗决策（包括免疫治疗资格）中需要考虑的重要因素。 什么是新的？ 在结直肠癌中，肿瘤及其微环境中肿瘤浸润淋巴细胞水平升高与生存率提高相关。然而，这种预后益处是否因肿瘤位置而异尚不清楚。在此，研究了 CD3+、CD8+ 和 FoxP3+ 肿瘤浸润 T 细胞对肿瘤位置的预后影响。数据将高 CD8+ 密度与右侧肿瘤的良好预后联系起来，将高 FoxP3+ 密度与改善直肠肿瘤的预后联系起来，将 CD3+ 密度与改善右半结肠和直肠肿瘤的预后联系起来。了解肿瘤位置不同的免疫系统反应可能有助于免疫调节疗法的开发。
Accumulating evidence demonstrates an association between dense infiltration of lymphocytes and prognosis in colorectal cancer (CRC), but whether this prognostic impact differs by tumour location remains unknown. This study investigated the prognostic impact of cytotoxic and regulatory T cells in CRC, with particular reference to the anatomical subsite of the primary tumour. The density of CD3+, CD8+ and FoxP3+ tumour‐infiltrating T cells was calculated in tissue microarrays with tumours from 557 incident CRC cases from a prospective population‐based cohort. Kaplan–Meier and Cox regression analyses were applied to determine the impact of high and low lymphocyte density on 5‐year overall survival, in subgroup analysis of right colon, left colon and rectum. High CD8+ cell density was a favourable prognostic factor for patients with right‐sided colon tumours (hazard ratio [HR]=0.53, 95% confidence interval [CI] 0.29–0.95), independent of age, sex, TNM stage, differentiation grade and vascular invasion, with a significant prognostic interaction between CD8+ cells and right‐sidedness (p = 0.031). High FoxP3+ cell density was an independent favourable prognostic factor only in patients with rectal tumours (HR = 0.54, 95% CI 0.30‐0.99), and CD3+ cell density was an independent favourable prognostic factor for tumours in the right colon and rectum, but there was no significant prognostic interaction between CD3+ or FoxP3+ cells and sidedness. These results demonstrate that the prognostic impact of tumour‐infiltrating lymphocytes in CRC differs by primary tumour site, further indicating that tumour location may be an important factor to take into consideration in therapeutic decisions, including eligibility for immunotherapy. What's new? In colorectal cancer, elevated levels of tumor‐infiltrating lymphocytes in the tumor and its microenvironment are associated with improved survival. Whether this prognostic benefit differs according to tumor location, however, is unknown. Here, the prognostic impacts of CD3+, CD8+ and FoxP3+ tumor‐infiltrating T cells were examined with respect to tumor location. The data link high CD8+ density with favorable prognosis for right‐sided tumors, high FoxP3+ density to improved prognosis for rectal tumors and CD3+ density with improved prognosis for right colon and rectal tumors. Knowledge of variable immune system responses by tumor location could help inform the development of immune‐modulating therapies.
登录
查看更多内容
影响因子：
45.3
作者：
Salama, Paul;Phillips, Michael;Iacopetta, Barry
通讯作者：
Iacopetta, Barry
影响因子：
82.9
作者：
Kononen, J;Bubendorf, L;Kallioniemi, OP
通讯作者：
Kallioniemi, OP
影响因子：
5.2
作者：
Minoo, P.;Zlobec, I.;Lugli, A.
通讯作者：
Lugli, A.
DOI：
10.1111/j.1749-6632.2009.04939.x
发表时间：
2009-01-01
期刊：
CANCER VACCINES
影响因子：
--
作者：
Rech, Andrew J.;Vonderheide, Robert H.
通讯作者：
Vonderheide, Robert H.
影响因子：
82.9
作者：
Curiel, TJ;Coukos, G;Zou, WP
通讯作者：
Zou, WP